First-in-human Phase I study of EZN-4176, a locked antisense oligonucleotide (LNA-ASO) to exon 4 of the androgen receptor (AR) mRNA in patients with castration-resistant prostate cancer (CRPC)

Diletta Bianchini, Aurelius Omlin, Carmel Jo Pezaro, David Lorente, Roberta Ferraldeschi, Deborah Mukherji, Mateus Crespo, Ines Figueiredo, Susana Miranda, Ruth Riisnaes, Andrea Zivi, Aby Buchbinder, Dana E Rathkopf, Gerhardt Attard, Howard I Scher, Johann S De Bono, Daniel C Danila

Research output: Contribution to journalArticleResearchpeer-review

54 Citations (Scopus)
Original languageEnglish
Pages (from-to)2579 - 2586
Number of pages8
JournalBritish Journal of Cancer
Volume109
Issue number10
DOIs
Publication statusPublished - 2013
Externally publishedYes

Cite this